AEON Biopharma, Inc. (AEON) stock
Close on Nov 11, 2026Market cap $8.55MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $8.55M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$54.62M
- EPS, diluted
- -$3.95
- Free cash flow
- -$17.31M
- Book value per share
- -$0.30
- Diluted shares
- 51M
Trading
- Next earnings
- Nov 13, 2026 (estimated, before the open)
- Previous close
- $0.18
- Open
- $0.18
- Day's range
- $0.17 – $0.18
- Volume
- 201,521
- Average volume (20 days)
- 873,766
- Beta (5 years)
- 0.74
- 52-week range
- $0.13 – $1.45
- RSI (14 days)
- 35.3
- Volatility (1 year)
- 109.7%
- Relative volume
- 0.03×
- WACC
- 8.6%
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | AEON | S&P 500 | Difference | AEON per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -37.9% | -2.4% | −35.5 pts | ||
| 3 months | -37.2% | -1.2% | −36.1 pts | ||
| Year to date | -84.4% | +12.3% | −96.7 pts | ||
| 1 year | -81.6% | +12.4% | −94.0 pts | ||
| 3 years | -99.9% | +78.8% | −178.8 pts | -91.7% | +21.4% |
| 5 years | -100.0% | +75.2% | −175.1 pts | -81.1% | +11.9% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases AEON Biopharma filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Results
- Update
- News
About AEON Biopharma
Pharmaceutical Preparations
AEON Biopharma, Inc. is a biopharmaceutical company focused on developing its lead drug candidate, ABP-450, as a biosimilar to Botox for debilitating medical conditions. The company advances ABP-450 through the biosimilar regulatory pathway exclusively for therapeutic indications rather than cosmetic uses. ABP-450 is a botulinum neurotoxin complex intended to treat disorders such as cervical dystonia, spasticity, and chronic migraine. AEON plans to market and distribute the treatment directly to healthcare providers, physicians, and health systems operating within physician-administered medical environments.
Company profile, executives and historyAEON Biopharma stock: common questions
What is AEON Biopharma's stock price?
AEON closed at $0.17 on Nov 11, 2026, down 4.41% on the day. Over the past 52 weeks it traded between $0.13 and $1.45.
What is AEON Biopharma's market cap?
AEON Biopharma was worth $8.55M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is AEON's P/E ratio?
AEON Biopharma lost money over fiscal 2025 (diluted EPS -$3.95), so it has no meaningful P/E ratio.
Does AEON Biopharma pay a dividend?
No. AEON Biopharma has not paid a cash dividend over the last twelve months.
When does AEON Biopharma report earnings next?
AEON Biopharma is expected to report Q3 FY2026 results on Nov 13, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has AEON stock performed over the past year?
Including dividends, AEON returned -81.6% over the past year, against +12.4% for the S&P 500.
Who are AEON Biopharma's competitors?
Companies most similar to AEON Biopharma by business, industry and size include EOLS, DWTX, XENE, ACAD, ANIP.
See a number that looks wrong?